AI-extracted from the 10-Q filed 2026-08-06 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Teleflex Q2 revenue rose 28.9% to $570.3M driven by $99M from BIOTRONIK Vascular Intervention acquisition, but gross margin contracted 190 bps to 58.2% due to tariffs and integration costs.
Biggest Revenue Drivers
Vascular$246.3M+9.0% YoY
Includes VI Business acquisition contribution and organic growth in existing products.
Surgical$112.1M+9.0% YoY
Reflects increases in sales volumes of existing products.
Biggest Revenue Drivers
Total revenue: $570.3M+28.9% YoY
Vascular$246.3M+9.0% YoY
Includes VI Business acquisition contribution and organic growth in existing products.
Surgical$112.1M+9.0% YoY
Reflects increases in sales volumes of existing products.
Largest Expense Items
Cost of goods sold$238.6M+35.0% YoY
Increased due to VI Business operations, tariff impacts enacted in 2025, and amortization of intangible assets from acquisition.
Selling, general and administrative$213.5M+55.4% YoY
Increased primarily due to operating and integration expenses of VI Business, unfavorable foreign currency hedging results vs prior year, and Strategic Divestitures restructuring costs, partially offset by $25M litigation settlement gain.
Interest expense$28.0M+28.9% YoY
Increased due to higher average outstanding debt from VI Business acquisition funding, partially offset by lower average interest rates on variable rate debt.
Margins: Gross margin declined 190 basis points to 58.2%, driven by tariff impacts from 2025 enactments, the lower-margin VI Business profile, and intangible asset amortization from the acquisition. SG&A expenses surged as a percentage of sales to 37.4% from 31.1%, primarily reflecting VI Business operating and integration costs and unfavorable year-over-year foreign currency hedging comparisons.
Watch Items from the Filing
Gross margin compressed 370 bps YTD to 57.1%, with tariffs and VI Business integration cited as primary drivers; further tariff developments could materially impact margins and cash flows.
Strategic Divestitures of Acute Care, IU, and OEM businesses ($2.0B proceeds) completed for OEM ($1.5B) on August 3, 2026; Acute Care/IU sale expected Q4 2026 subject to regulatory approvals.
Three restructuring plans underway with combined estimated charges of $76–$93M: Strategic Divestitures ($31–$37M), VI integration ($36–$44M), and 2023 Footprint realignment ($9–$12M).
Pending Palette acquisition litigation seeking $46.7M in contingent milestone payments; dispute involves tax indemnification rights and potential offset against amounts owed; outcome and financial exposure currently indeterminable.
Italian payback obligation reserve reduced to $21.5M after parliament enacted 2025 modification reducing amounts owed by 75%; further changes to healthcare reimbursement or regulations could impact reserves.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
Krakauer Andrew ADirectorGrant or award · May 15, 2026
Ryu JaewonDirectorGrant or award · May 15, 2026
Hicks Cameron PCorp. VP & Chief HR OfficerShares withheld for tax or exercise price · Mar 4, 2026
Congress trading in TFX
7 transactions in TFX reported by 5 members of Congress under the STOCK Act, most recent trade Jul 22, 2025. Reported transactions, not recommendations.
About TELEFLEX INC (TFX): stock profile, AI score and financials
TELEFLEX INC (TFX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TFX at 35.1/100 on a composite quality score built from its SEC filings, placing it at rank #2,306 of 2,925 stocks — the bottom half of the AI-ranked universe. Areas of concern include profitability (11.6) and balance sheet strength (13.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 48.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), TELEFLEX INC reports quarterly revenue of $570.3M, net income of $99.7M, an operating margin of 12.8%. Top institutional holders of TFX by reported 13-F value include BlackRock, Jupiter Topco, T. Rowe Price Investment Management, based on the most recent SEC filings. TFX trades on the NYSE exchange and files with the SEC under CIK 96943. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TFX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for TELEFLEX INC directly from SEC EDGAR.